Pfizer (NEOE:ZPFE) 1-Year Sharpe Ratio: N/A (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NEOE:ZPFE Pfizer Inc NEOE:ZPFE
57 GF Score
Price C$9.51
GF Value C$9.78
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Pfizer 1-Year Sharpe Ratio?

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-29), Pfizer's 1-Year Sharpe Ratio is Not available.

Pfizer  (NEOE:ZPFE) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Pfizer 1-Year Sharpe Ratio Related Terms

NEOE:ZPFE vs BMY, GILD, AMGN: 1-Year Sharpe Ratio Comparison

For the Drug Manufacturers - General subindustry, Pfizer's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pfizer 1-Year Sharpe Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Pfizer's 1-Year Sharpe Ratio falls into.


NEOE:ZPFE
57GF Score
Pfizer Inc NEOE:ZPFE
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pfizer 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Is Pfizer (NEOE:ZPFE) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be undervalued. The current stock price of C$9.51 is trading 2.8% below its estimated GF Value™ of C$9.78. GuruFocus considers Pfizer to be Fairly Valued.

Key valuation signals for NEOE:ZPFE:

  • 1-Year Sharpe Ratio: N/A
  • GF Value™: C$9.78 vs. price of C$9.51 (2.8% below fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the NEOE:ZPFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
57GF Score

Get the complete analysis for NEOE:ZPFE

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$9.51
Price
C$9.78
GF Value